An Evidence Based Approach to Colorectal Cancer Screening
-
Upload
geraldine-travis -
Category
Documents
-
view
28 -
download
1
description
Transcript of An Evidence Based Approach to Colorectal Cancer Screening
An Evidence Based Approach to Colorectal Cancer Screening
J. C. Ryan, M.D.
Associate Professor of Medicine UCSF and SF VAMC
9/22/2014
Colorectal Cancer
• Lifetime incidence of 6%
• Common cause of cancer death, 2nd in men, 3rd in women
• Well defined precursor lesion (adenoma) with long lag time until the development of cancer
• Reasonable target for screening
USPSTF CRC Screening Recommendations
• Colonoscopy q10 yr
• Flex Sig q5 yr
• Fecal Testing q1 yr
• Flex Sig q5 yr and FOBT q1 yr
• ACBE/CT colography q5 yr
Colonoscopy of Asymptomatic Patients
37.7% have colorectal neoplasia:
27% TA <10 mm
5% TA >10 mm
3% Villous adenoma
1.7% High grade dysplasia/CIS
1.0% Invasive cancer
Screening Sigmoidoscopy
• Will detect 70% of patients with colonic neoplasia
• Distal adenomas on sig prompt colonoscopy
• 30% of patients (with only right sided neoplasia) will be missed
• Will reduce cancer from 6% to 2% in the population
Colon Cancer Risk Reduction
• Colonoscopy: 6% to <0.5%
• Flex Sig: 6% to 2.0%
• Fecal Occult blood?
HemoccultTesting
• Minnesota, 1994 NEJM: 33% improved cancer survival
• UK, 1997 NEJM: 15% improved cancer survival
• Denmark, 1997 NEJM: 18% improved cancer survival
Theoretical test 99.5% sensitive and specific
• 1000 pts from high risk (50%) population:
– 500 true pos, 5 false pos
– Predictive value 500/505
• 1000 pts from low risk (0.5%) population:– 5 true pos, 5 false pos– Predictive value 5/10
Similar test, 90% sensitive and specific
• 1000 pts from high risk population:– 500 true pos, 100 false pos– Predictive value 500/600 = 83%
• 1000 low risk patients:– 5 true pos, 100 false pos– Predictive value 5/105 = 4%
Performance characteristics of FOBT?
• Noncolonoscopically controlled trial in patients with advanced neoplasia:– Up to 79.4% sensitive with select tests (NEJM.
334:155.1996)
• Noncolonoscopically controlled trial in largely symptomatic cancer pts: – 66% sensitivity (Ann Int Med.112:328.1990)
FOBT 66-79% Sensitive?
• Trials did not focus on asymptomatic patients? (not average risk)
• Not colonoscopically controlled (Only FOBT+ patients were colonoscoped)
• “Those with great enthusiasm have no controls and those with great controls have no enthusiasm”
Colonoscopically Controlled Trials of Hemoccult II
–Imperiale, et al, NEJM. 351:2704. 2004 -Lieberman. NEJM. 345:555. 2002
Imperiale N = 2507 Std HC-II Lieberman N = 2885 Rehyd HC-II
Patient group FOBT+ FOBT- % Positive FOBT+ FOBT- % Positive
Total patients 144 2361 5.8% 239 2646 8.6%
No neoplasia 82 1702 4.6% 98 1559 5.9%
Adenoma <10 mm 15 271 5.2% 68 817 7.7%
Advanced adenoma 43 360 10.7% 61 258 23.4%
Cancer 4 27 12.9% 12 12 50%
Fecal blood testing (Hemoccult II)
• Essentially random test that is positive leads to colonoscopy 6% of the time
• Over 10 yr, [1- (0.94)10] = (1 - 0.53) = 47% of patients eventually will be FOBT+ and receive colonoscopy
• 2.5% of SFVA patients aged 50-75 every year get a symptom generated colonoscopy (25% over 10 yrs)
• Total colonoscopies over 10 yr period is approx 71% in FOBT screening programs
Screening Resources per 10,000 Patients/10 yr
• CF Program (20% refuse screening):– 8,000 (80%) total naïve colonoscopies (screening
and symptom generated)
• Annual FOBT 6% positive rate: – 76,896 x 3 = 230,688 FOBT tests– 4,620 colonoscopies for +FOBT over 10 yr– 2500 symptom generated colonoscopies
(screened nonetheless) over 10 yr– 7120 (71%) total naïve colonoscopies
Is Hemoccult II useful in conjunction with Flex sig?
• Flex Sig alone:– 70.3% of pts with neoplasia detected
• Flex Sig plus one time FOBT:– 75.8% of pts with neoplasia detected– 5.0% more colonoscopies needed to detect
the additional 5.5% of patients
(Lieberman, NEJM 2002)
All Studies
Studies with: Colonoscopic controls
Asymptomatic screening age patients
Varying the FIT Cutoff Alters Cancer Specificity
Study Levi (2007)
N 1204 Park (2010)
N 770 DeWijk(2012)
N 1256
Cutoff % Pos Adv Ad Cancer % Pos Adv Ad Cancer % Pos Adv Ad Cancer
50 17% NR 72% 14.2% 44.1% 12/13 (92.3%) 10% 35.4% 7/8 (88%)
75 12.5% NR 67% 12.3% 37.3% 12/13 (92.3%) 6.6% 31% 6/8 (75%)
100 11.6% NR 61% 11.3% 33.9% 12/13 (92.3%) 5.6% 29.2% 6/8 (75%)
125 9.8% NR 53% 10% 28.8% 11/13 (84.6%)
150 9.4% NR 53% 7.9% 27.1% 11/13 (84.6%)
Only: Colonoscopic controls
Asymptomatic screening age patients
FIT positive <10%
Hi Quality FIT Studies
Study N % Positive Sens AA Sens CRC
Levi (2007) 1000 9.4% NR 53%
Morikawa (2005) 21,805 5.6% 27.1% 65.8%
Chiu (2013) 18,296 7.3% 28% 78.6%
Brenner (2013) 2235 5.0% 23.4% 60.0%
Brenner (2013) 2235 5.0% 20.4% 53.3%
Brenner (2013) 2235 5.0% 25.7% 73.3%
Colonoscopy
• Nearly 100% sensitive for the detection of cancer, 91% for polyps
• National Colon Polyp Study predicts that colonoscopy will diminish colon cancer risk from 6% to <0.5% and will prevent death from colon cancer
Cost per year of life saved
• Flex Sig every 5 yr $23K• Flex Sig plus annual FOBT $80K• FOBT annually $80-220K• Colonoscopy every 10 years $5.6K• Dialysis $55K• Mammography $80-140K?• Pap Smears $70-120K• Air bags $450K
SF-VAMC GI Unit44,000 screening age pts
• 1994: Commitment to CF strategy• 1996: Only 57 screening colonoscopies• 1998: Direct screening and scheduling by GI nurses• 1999: Telephone scheduling by GI nurses• 1999: Elimination of routine clinic visits for path FU• 1997-2003: Marked increase in exams for even
minimal chronic symptoms (de facto screening)• 2002-2005: Steady state reached at 76-79% with
CRC screening from reminder data
CRC at the SF-VAMC
• 1995-2000: 486 (81 cases/year)
• 2001: 52 cases
• 2002: 26 cases
• 2003: 16 cases
• 2004: 11 cases
• 2005: 13 cases
Total 118 cases
SF VAMC CRC 2001-2005
• 118 cases, 108 of whom were from our minority (21%) unscreened population
• 10 cases occurred in our previously screened (79%) surveillance population– 7 had villous elements in index polyps– 3 had delayed colonoscopic surveillance
Conclusions• Endoscopic screening methods (Colon and Flex Sig)
are acceptable methods for CRC prevention• Fecal testing is beneficial in that it prompts a
screening colonoscopy• Fecal testing does not reduce colonoscopy demands
and Hemoccult-II misses >87% of colon cancers in screening patients
• Practitioners who use Fecal testing as primary screening have been successfully sued for missed cancers
• The majority of positive fecal tests do not have advanced neoplasia (false positive)
Special Consult Considerations
• Request for colonoscopy in patient with FOBT+ despite negative screening colon 2 yr ago. No anemia or symptom.
• Request for colonoscopy in patient with FOBT+ despite negative screening colon 2 yr ago. No anemia or symptom.
• If the majority of positive FOBT+ are false positive, nearly all positive FOBT in those with up to date colonoscopy are false positive
• Recommendation: “Please discontinue Fecal testing”
Special Consult Considerations
Special Consult Considerations
• Request for colonoscopy in patient with negative screening colon 2 yr ago because his spouse was dx’ed with CRC and he is “worried” about cancer. No anemia or symptoms.
Special Consult Considerations
• Request for colonoscopy in patient with negative screening colon 2 yr ago because his spouse was dx’ed with CRC and he is “worried” about cancer. No anemia or symptoms.
• Recommendation: Please tell this patient not to worry anymore. A complication from an unindicated colonoscopy is very difficult to defend!
Special Consult Considerations
• Request for colonoscopy due to new onset constipation or a solitary episode of hematochezia. Patient with screening colon 2 yr ago showing no neoplasia. No anemia or other symptoms.
Special Consult Considerations
• Request for colonoscopy due to new onset constipation or a solitary episode of hematochezia. Patient with screening colon 2 yr ago showing no neoplasia. No anemia or other symptoms.
• Most CRC sx manifest in the distal colon. Recommend examine distal colon with Flex Sig
Special Consult Considerations
• Request for colonoscopy due to new onset recurrent hematochezia over 2 months. Patient with screening colon 2 yr ago showing no neoplasia. Hct 36 no other symptoms.
• Recommendation: Repeat colonoscopy to look for missed lesions
Acknowledgements
• Ann Hayes, R.N. and Ken McQuaid, M.D.
• The nurses of the San Francisco VA GIDC